Not yet recruiting NCT07326631
Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Finerenone.
- Who it may be relevant to
- Registry conditions: Diabetic Kidney Disease (DKD), Heart Failure. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.
Interventions
- Drug Finerenone
To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.
Primary outcome measures
- Number of Participants with Renal Function Decline post finerinone therapy [Time frame: From enrollment to the end of treatment at 06 months]
- Number of Participants with Heart Failure (HF) Event post finerinone therapy [Time frame: 6 month]
- eGFR Measurement [Time frame: 06 months]
- Number of Participants with Albuminuria [Time frame: 06 months]
- Number of Participants with Hyperkalaemia post treatment [Time frame: 06 months]
- Number of Participants with Cardiovascular (CV) Event post treatment with finerinone therapy [Time frame: 06 months]
Eligibility criteria
Inclusion criteria
- Adults aged ≥18 years.
- Diagnosed cases of type 2 diabetes mellitus.
- Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
- On stable ACE inhibitor or ARB therapy for at least 4 weeks.
- Serum potassium ≤4.8 mmol/L.
- Provided written informed consent.
Exclusion criteria
- Symptomatic heart failure (NYHA class II-IV).
- eGFR <25 mL/min/1.73m² or on maintenance dialysis.
- Known non-diabetic kidney disease.
- Recent major cardiovascular event (within 30 days).
- Serum potassium >4.8 mmol/L or history of severe hyperkalaemia.
- Contraindication or hypersensitivity to finerenone.
- Pregnancy or lactation.
- Any condition limiting compliance or follow-up.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07326631 · 22126